TY - JOUR T1 - A phase II study of irinotecan combined with S-1 in patients with advanced or recurrent cervical cancer previously treated with platinum based chemotherapy JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - 474 LP - 479 DO - 10.1136/ijgc-2018-000070 VL - 29 IS - 3 AU - Seiji Mabuchi AU - Eriko Yokoi AU - Kotaro Shimura AU - Naoko Komura AU - Yuri Matsumoto AU - Kenjiro Sawada AU - Aki Isobe AU - Tateki Tsutsui AU - Fuminori Kitada AU - Tadashi Kimura Y1 - 2019/03/01 UR - http://ijgc.bmj.com/content/29/3/474.abstract N2 - Objectives We conducted a phase II study to investigate the efficacy and toxicities of irinotecan plus oral S-1 in patients with advanced or recurrent uterine cervical cancer.Methods Patients with advanced or recurrent cervical cancer previously treated with platinum based chemotherapy were enrolled. Irinotecan (150 mg/m2) was administered intravenously over the course of 90 min on day 1, and S-1 (80 mg/m2) was given orally in two divided doses from days 1 to 14 of a 21 day cycle. The primary endpoint of this phase II study was response rate. Secondary endpoints included safety, progression free survival, and overall survival.Results A total of 19 patients were enrolled and treated. The response rate was 29.4%. Grade 3–4 hematologic toxicities were observed in three patients (15.7%). The only grade 3–4 non-hematologic toxicity observed was grade 3 diarrhea. The median progression free survival and overall survival were 3 months and 9 months, respectively.Conclusion S-1 plus irinotecan in a 3 weekly setting is safe and active in women with advanced or recurrent cervical cancer previously treated with platinum based chemotherapy. Future corroborative clinical studies are warranted. ER -